The US FDA’s Vaccines and Related Biological Products Advisory Committee voted Thursday to recommend emergency use authorization (EUA) of Moderna’s coronavirus vaccine. The FDA will now review the advisory committee's vote and decide whether to authorize emergency use nationwide.

FDA Moderna Briefing Document (PDF)

FDA Statement on Vaccines and Related Biological Products Advisory Committee Meeting

The excitement and expectations associated with the Moderna vaccine cannot be overstated and it will surely benefit non-hospital based outpatient physicians and staff. It is more easily transported and stored, making it more accessible to broader groups, including independent physician practices located in both suburban and rural areas. Unlike Pfizer, it can be stored at normal freezer temperatures and it comes in much smaller batches.

Last week, Maine CDC released initial projections that 24,200 doses are expected for first week of a Moderna delivery. Of the 24,200 total, 22,700 will go to hospitals and another 1,500 to be split between Androscoggin Home Health Services, Mid Coast Parkview Health (CHANS), MaineHealth Care at Home, Houlton Band of Maliseets, and Maine EMS.

Related FDA information:

COVID-19 Vaccines (FDA)

COVID-19 ACIP Vaccine Recommendations (ACIP)

Emergency Use Authorization for Vaccines Explained

Emergency Use Authorization for Vaccines to Prevent COVID-19

Development and Licensure of Vaccines to Prevent COVID-19

Washington Post: FDA vows to move 'rapidly’ to authorize second coronavirus vaccine